Q-omics provides the consensus-scored IL17B profile across patient tissues and cancer cell-line models. IL17B expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, IL17B is differentially expressed in 12, with the highest sampling consensus in BLCA. Additionally, IL17B protein abundance shows 26,474 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRP, BLCA, and GBM as cancer lineages where IL17B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IL17B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IL17B survival associations across molecular data types. IL17B RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IL17B RNA expression–survival associations across cancer types. High IL17B expression shows unfavorable associations in KIRP, LIHC, LGG, READ and HNSC, but favorable associations in BRCA. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for IL17B RNA expression.
This table summarizes IL17B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in BLCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for IL17B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IL17B shows lower tumor expression in BLCA, KICH, KIRP, BRCA and UCEC and higher tumor expression in LIHC. The BLCA box plot shows higher IL17B RNA expression in normal versus tumor tissue (log2 FC = −1.100, t-test p < 0.001).
This table shows molecular features associated with IL17B in patient tissues and cancer cell lines. In patient samples, IL17B shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, IL17B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BONE.
